A pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Looks like time to go long Salix.
Large short position in company and they have had their way of late. At current $10 range, stock offers strong value - mid teen ROE, strong balance sheet and good growth prospects including potential XIFAXAN. Current price discounts most uncertainty and provides decent candidate for gastrointestinal short squeeze on FDA news or potential bid.